Kamada (KMDA) EBT Margin (2012 - 2026)
Kamada's (KMDA) quarterly EBT Margin came in at 18.55% in Q2 2026, up 570.0% on a YoY basis from 2.77% in Q2 2025, and up 55.68% quarter-over-quarter from 11.92% in Q1 2026.
Powered by 
Analysis
Kamada (KMDA) EBT Margin (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported EBT Margin for 15 consecutive years, with 18.55% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin rose 570.0% year-over-year to 18.55%; the trailing twelve-month figure through Jun 2026 stood at 13.91% (up 283.0% YoY), and the FY2025 full-year result was 13.0%, up 472.0% from the prior year.
- EBT Margin grew to 18.55% in Q2 2026 per KMDA's latest filing, from 11.92% in the prior quarter.
- Across five years, EBT Margin topped out at 18.55% in Q2 2026 and bottomed at 16.58% in Q2 2022.
- Historically, EBT Margin has averaged 6.78% across 5 years, with a median of 9.07% in 2023.
- The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 2045 bps in 2022, then soared 2167 bps in 2023.
- Over 5 years, EBT Margin stood at 6.48% in 2022, then surged by 113 bps to 13.79% in 2023, then plunged by 54 bps to 6.3% in 2024, then soared by 68 bps to 10.6% in 2025, then soared by 75 bps to 18.55% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 18.55%, 11.92%, and 10.6% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn | -20,427.46% |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn | 18.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.55% |
| Mar 31, 2026 | 11.92% |
| Dec 31, 2025 | 10.60% |
| Sep 30, 2025 | 13.54% |
| Jun 30, 2025 | 12.85% |
| Mar 31, 2025 | 15.02% |
| Dec 31, 2024 | 6.30% |
| Sep 30, 2024 | 9.46% |
| Jun 30, 2024 | 10.57% |
| Mar 31, 2024 | 6.46% |
| Dec 31, 2023 | 13.79% |
| Sep 30, 2023 | 8.69% |
| Jun 30, 2023 | 5.09% |
| Mar 31, 2023 | -5.85% |
| Dec 31, 2022 | 6.48% |
| Sep 30, 2022 | 1.53% |
| Jun 30, 2022 | -16.58% |
| Mar 31, 2022 | -6.36% |
| Dec 31, 2021 | -14.82% |
| Sep 30, 2021 | -3.67% |